The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

AstraZeneca (AZN.L, AZN.ST) on Monday said Enhertu plus pertuzumab won approval in the US as the first-line treatment of ...

(Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in ...

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...

Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments ...

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

(Alliance News) - AstraZeneca PLC on Monday said enhertu plus pertuzumab has been approved in the US as a first-line treatment of patients with HER2-positive metastatic breast cancer.

The US Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line ...

Acupuncture may improve both perceived and objectively measured cognitive difficulties in breast cancer survivors, a ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary ...